Hofseth Biocare ASA: EXTRAORDINARY GENERAL MEETING CONCLUDED
04 Janvier 2024 - 2:02PM
Hofseth Biocare ASA: EXTRAORDINARY GENERAL MEETING CONCLUDED
Hofseth Biocare ASA ("HBC" or the "Company") has
today, on 4 January 2024, completed an extraordinary general
meeting. All items proposed on the agenda were adopted, including
the share capital increase of new preference class B shares in
connection with the NOK 144 million investment from Hofseth
International AS announced on 13 December 2023.
The minutes from the meeting in Norwegian and
English are enclosed.
For further information, please
contact: Jon Olav Ødegård, CEO at HBC Phone: +47 936 32
966 E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:HBC is a Norwegian
consumer and pet health ingredient supplier and an incubator for
new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate
inflammation and the immune response with pre-clinical studies
ongoing in multiple clinics and university research labs. Lead
clinical and pre-clinical candidates are focused on developing an
oral treatment for inflammatory disease driven by eosinophils (a
type of white blood cell). Clinical trial work with the oil is
ongoing to ameliorate lung inflammation in eosinophilic asthma and
COPD ("smokers lung").
Other leads are focused on using the Company’s
bioactive peptides as a Medical Food for the protection of the
Gastro-Intestinal (GI) system against inflammation (including
ulcerative colitis and the orphan condition necrotizing
enterocolitis).
The Company is founded on the core values of
sustainability, optimal utilization of natural resources and full
traceability. Through innovative and patent protected hydrolysis
technology, HBC can preserve the quality of the lipids, proteins
and calcium from fresh salmon off-cuts.
HBC's headquarters are in Ålesund, Norway with
offices in Oslo, London, Zürich, New Jersey and Palo Alto, CA.
This information is subject to the disclosure
requirements pursuant to section 5-12 of the Norwegian Securities
Trading Act.
- HBC Minutes EGM 04JAN2024
Hofseth Biocare Asa (LSE:0Q6H)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Hofseth Biocare Asa (LSE:0Q6H)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025